Lactic Acidosis in a Man with Diabetes: Is Metformin the Culprit?

Harsha Anuruddhika Dissanayake1, Eranga Wijewickrama2 and Prasad Katulanda1,2

1Diabetes Research Unit, Faculty of Medicine, University of Colombo, Sri Lanka
2Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka

Abstract

Background: Lactic acidosis is a rare but serious adverse effect of metformin, particularly when used in high doses in patient with other risk factors. We report a case of metformin associated lactic acidosis that improved with hemodialysis.

Case presentation: Seventy-year-old male with diabetes and stage IV chronic kidney disease presented with vomiting and was found to have lactic acidosis with lactate of 8 mmol/L while being on metformin 1 g thrice daily. He was successfully managed with haemodialysis and supportive care.

Conclusion: This case illustrates the importance of judicious drug prescription in patients with multiple comorbidities; need to consider metformin induced lactic acidosis in appropriate settings and importance of active management with haemodialysis. Recommendations on prevention and options for treatment are also be discussed.

Keywords: Metformin; Lactic acidosis; Chronic kidney disease; Diabetes

Background

Metformin is the first line agent in the treatment of type 2 diabetes mellitus [1]. It is also used in management of metabolic syndrome and polycystic ovary syndrome [2]. Metformin acts by reducing hepatic glucose production and increasing insulin sensitivity of peripheral tissues [3]. Metformin is eliminated unchanged by the kidneys [4]. It has a half-life of 2-8 hours, but is longer in renal impairment [5].

Metformin is very effective in glycaemic control, has favourable cardiovascular outcomes, and improves lipids and fatty liver disease [6]. It also has a favourable safety profile with minimal hypoglycaemia and being weight neutral or in some patients can cause weight loss [7]. Gastrointestinal disturbances are the commonest side effects. In overdose it is known to cause hypotension, hypothermia and altered consciousness as well as hypoglycaemia which is exacerbated by co-treatment with ACE inhibitor [8].

Lactic acidosis is a rare complication of metformin therapy [3]. Its incidence in different case series have ranged from 3 to 47 per 100000 patient years [9]. However a recent review of prospective and observational studies concluded no increased risk over other oral hypoglycaemic agents [10]. Phenformin, the other biguanide that was in use, was withdrawn from the market in late 1970’s due to high rate of phenformin induced lactic acidosis [11,12]. However incidence of metformin associated lactic acidosis remains much less and virtually unseen even in some settings where large numbers of diabetic patients are managed over many years.

Metformin induced lactic acidosis (MILA) refers to lactic acidosis in a patient on metformin in the absence of other recognized risk factors or causes for lactic acidosis whereas metformin associated lactic acidosis (MALA) is the term to describe when such risk factors also coexist [8].

We describe a patient who developed lactic acidosis while on high dose metformin.

Case Presentation

A 70-year-old male presented with nausea, vomiting and malaise progressively worsening over 3 days and reduced urine output on the third day. He denied fever, dysuria, cough, dyspnea, chest pain, headache or diarrhea. He had diabetes mellitus for 20 years, hypertension and stable angina for 3 years and had been recently detected to have chronic kidney disease. He had been on metformin 1 g thrice daily for more than 5 years along with gliclazide, enalapril, atorvastatin and low dose aspirin. The same regimen had been continued despite of having a recent (one month before admission) serum creatinine level of 2.4 mg/dL due to delays in follow up.

On admission he was ill, drowsy, dehydrated and had a pulse rate 104 beats per minute, blood pressure of 100/60 mmHg, respiratory rate of 32 per minute, temperature of 98.8°F and SpO2 of 98% in room air. System examination did not reveal any abnormalities.

Investigations showed normochromic normocytic anaemia (haemoglobin 10.2 g/dL), normal total leucocyte count and differential, CRP of 10 mg/L (normal<6 mg/L) and normal random capillary blood glucose (145 mg/dL). Blood biochemistry detected hypernatraemia (129 mmol/L), hypokalaemia (3.45 mmol/L) and elevated serum creatinine (5.4 mg/dL). Liver biochemistries were normal.

Urinalysis detected 10-15 pus cells per high power field in centrifuged sample. Urine and blood cultures did not isolate any microorganisms. Abdominal ultrasonography only showed evidence of...
chronic renal parenchymal disease. Twelve lead electrocardiogram and echocardiogram were normal.

Arterial blood gas analysis showed severe metabolic acidosis with hyperlactataemia (pH 7.17, PCO$_2$ 11.6 mmHg, PO$_2$ 123.0 mmHg, HCO$_3$ 5.4 mmol/L, base deficit 23.4 mmol/L and serum lactate 8 mmol/L (0.5-2.2) suggesting the diagnosis of severe lactic acidosis.

He was successfully resuscitated with crystalloid volume replacement. Metformin was withheld and empiric antibiotics were commenced for a presumed urinary tract infection. Despite these measures acidosis continued to worsen and he required four sessions of haemodialysis before his acidosis got corrected and lactate returned to normal.

He was commenced on biphasic insulin in place of metformin. During a follow up 4 weeks later his serum creatinine was stable at 2.6 mg/dL without further dialysis, and glycaemic control was satisfactory (HbA1c 7.6%, fasting plasma glucose 133 mg/dL). He was administering insulin by himself with the support of family members and had no major hypoglycaemic events.

Discussion

Severe metabolic acidosis in our patient was most likely to be a result of hyperlactataemia and acute kidney injury. High dose metformin in a background of renal dysfunction in the absence of other factors that would cause systemic hypoxia (such as sepsis or cardiac failure) makes metformin associated lactic acidosis (MALA) the most likely diagnosis. Although severe sepsis, hypotension, severe hypoxaemia, cardiac or hepatic failure can also cause lactic acidosis, absence of fever, near normal inflammatory markers, negative cultures, normal blood pressure and oxygen saturation, normal cardiac and liver function tests make those alternatives less likely.

Principle mechanism of MALA is thought to be inhibition of mitochondrial function in hepatocytes resulting in inhibition of aerobic oxidation and accumulation of lactate [13]. This explains why haemodialfiltration is effective in treatment as it removes metformin and lactate to negate acidosis. Therefore despite very low pH and high lactate, survival is better compared to lactic acidosis of other aetiologies. It is also postulated that metformin causes peripheral vasodilation by activating endothelial nitric oxide synthase (eNOS) [14] and in patients with sepsis, this may cause worsening of septic shock [8] and therefore lactic acidosis. eNOS activation as well as myocardial dysfunction secondary to severe acidosis might have contributed to fall in blood pressure in our patient.

Recommended maximum daily dose of metformin is 2 grams, in the absence of other co-morbidities [15]. Although it is accepted that metformin should be used cautiously in moderate renal impairment or be avoided altogether in advanced renal impairment, recommendations vary on exact cut offs [16]. For instance, Kidney Disease Outcomes Quality Initiative guidelines recommend metformin to be contraindicated if serum creatinine level exceeds 1.4 mg/dL in women or 1.5 mg/dL in men [17]. A consensus statement of American Diabetes association and European Association for the Study of Diabetes states metformin is safe (at a reduced dose) as long as eGFR is greater than 30 ml/min/1.73 m$^2$ [18]. This is consistent with the recommendations of Canadian Diabetes Association [19] and Australian Diabetes Society, although these two authorities differ slightly in their cut offs recommending caution; eGFR 30-45 ml/min/1.73 m$^2$ in the former and 30-60 ml/min/1.73 m$^2$ in the latter. Similarly, National Institute for Health and Clinical Excellence recommends caution if serum creatinine exceeds 1.5 mg/dL or eGFR falls below 45 ml/min/1.73 m$^2$ and to avoid metformin when serum creatinine is greater than 1.7 mg/dL or eGFR is below 30 ml/min/1.73 m$^2$ [20]. In our patient, metformin may have been commenced when eGFR was greater than 30 ml/min/1.73 m$^2$ but not adjusted to the increasing creatinine or falling eGFR.

Similarly metformin is contraindicated in liver failure, advanced heart failure or respiratory insufficiency, all of which are recognized risk factors for systemic hypoxia and lactic acidosis [21]. All these are recognized risk factors for metformin associated lactic acidosis [3]. In addition, severe acute illness with dehydration and co-therapy with NSAIDs, ACE inhibitors and antiretroviral treatment are also described as risk factors for MALA [5]. It is important to recognize that many patients with diabetes and ischaemic heart disease are on NSAIDs and ACE inhibitors along with metformin.

Early detection of MALA is important as well as difficult. Onset can be acute and often non-specific with general ill health, body ache, gastrointestinal symptoms [22] as in the case of our patient. Other features of metformin toxicity are hypotension, hypothermia, altered consciousness and hypoglycaemia [8]. High index of suspicion and appropriate evaluation of a patient on metformin presenting with these symptoms should be emphasized.

MALA is effectively treated by withdrawing metformin and haemodialysis which removes metformin from the circulation [23-26]. Therapeutic benefits of dichloroacetate, trihydroxy methyl aminomethane [26], as well as intravenous infusions of methylene blue [8] have been described in some cases. Frusemide (to increase metformin filtration rate), haemofiltration and continuous venovenous haemodiafiltration with bicarbonate replacement fluid are the other options described [22].

MALA in ICU setting has a 30% mortality rate [27]. However, these figures are better than what the pH and lactate levels would predict [28,29]. Although low pH and absence of renal failure [5] are described as poor prognostic factors, low pH and lactate levels are thought to be poor predictors of mortality in MALA [3]. Infact in some case series survivors have had higher lactate levels [30]. This is probably due to the fact that mitochondrial inhibition by metformin is easily reversed by haemodialysis irrespective of the pH or lactate level which are rapidly reversible [13]. Furthermore, reviewing recent literature Renda et al postulate that associated co-morbid risk factors are stronger predictors of mortality than the dose of metformin or degree of impairment of its elimination, in metformin intoxication [5]. Whether this applies same to inadvertent overdosing as in the case of our patient, remains uncertain.

Conclusion

Lactic acidosis is a rare complication of metformin therapy and its therapeutic benefits far outweigh the remote risk of lactic acidosis. However this case report highlights the importance of recognizing risk factors for metformin associated lactic acidosis and monitoring of renal functions and modifying the dose in high risk patients. With the rising prevalence of diabetes and increasing use of metformin a rise in this rare adverse effect can be anticipated. Mainstay of treatment includes supportive care, haemodialysis and withdrawal of metformin. A low pH or high lactate levels should not discourage active management as they are poor predictors of survival compared to lactic acidosis of other etiologies.
Declarations

Ethics approval
Not applicable

Consent to participate
Informed written consent was obtained from the patient for use of his medical information in compiling the manuscript.

Consent for publication
Patient gave written informed consent to publish the clinical details without breaching confidentiality.

Availability of data and material
Not applicable. All data used for the case report were from patients past medical records and investigation findings during hospital stay and carry the patient's identity. Authors do not wish to share that information in public to ensure confidentiality and since relevant information are noted in this report.

Competing interests
Nothing to declare

Funding
None

Authors' contributions
HAD collected data, reviewed literature and compiled the manuscript. ESW and PK critically reviewed the report.

Acknowledgement
Authors wish to acknowledge the staff of Diabetes Research Unit for assistance in data collection and patient and family for kind cooperation in provision of information.

References